

**Pulmonary Hypertension Global Patient Survey: a preliminary overview**

<sup>[1]</sup> University of Cambridge & Royal Papworth Hospital, Cambridge, UK  
<sup>[2]</sup> Royal Statistical Society, London - UK  
<sup>[3]</sup> Pulmonary Hypertension Association US, Washington, USA  
<sup>[4]</sup> Europejskie Centrum Zdrowia Otwock, Otwock, Poland  
<sup>[5]</sup> Great Ormond Street Hospital, London, UK  
<sup>[6]</sup> ERN-LUNG, Frankfurt, Germany  
<sup>[7]</sup> Pulmonary Hypertension Association Europe, Vienna, Austria  
<sup>[8]</sup> iOWNA Ltd., London, UK

J. Newman<sup>1</sup>, S. Munagala<sup>2</sup>, M. Granato<sup>3</sup>, M. Kurzyna<sup>4</sup>,  
 L. MacDonald<sup>5</sup>, G. Meszaros<sup>6</sup>, E. Otter<sup>7</sup>, M. Stone<sup>8</sup>,  
 M. Toshner<sup>1</sup>, M. Tschida<sup>7</sup>, J. Pepke-Zaba<sup>1</sup>

**Background**

- Pulmonary hypertension (PH) is caused by a range of conditions affecting people of **all ages in diverse ways**, with differing treatment options & prognoses
- Patients' experience of living with PH is likely to vary considerably within & **between countries**, but the extent of this variation is unknown
- **The first global patient survey**, co-designed & delivered through an international network, is needed to help improve patient outcomes


**Aim**

- To **understand patients' lived experience** to better inform clinical guidelines & research priorities


**Methods**

- Survey drafted via a consensus-building process by a **multi-disciplinary panel** of collaborators
  - **patients**, physicians, nurses, researchers, industry partners
  - advocates from Pulmonary Hypertension Associations (PHAs)
- Supported by PVRI & endorsed by ERN-Lung
- Online survey with over **100 questions** through 3 parallel responder streams:
  - adult patients
  - carers/relatives of adult patients
  - parents/guardians of paediatric patients
- Translated, tested & rolled out in **24 languages** from October 2023 for 2 months
- **Disseminated by PHAs** via traditional & social media
- Mixed-methods analysis - quantitative descriptive statistics (by region; by PH group) & qualitative thematic analysis


**Results - examples & early highlights**



**Quality of life (all adults with PH)**



**Time to diagnosis (adults with IPAH & HPAH)**



- **20%** of adults with Group 1 PAH have had genetic testing
- **19%** of all adult PH patients have taken part in a trial
- **60%** of all adult CTEPH patients have had PEA and/or BPA
- **74%** of all adult PH patients have had negatively impacted employment

**Conclusions**

- The scale and depth of patient-generated data in PH GPS helps to fill the knowledge gap regarding patients' perspectives
- The results from the survey will inform international clinical guidelines, research priorities and health policy, to improve care and outcomes of patients globally

With thanks to all patients, relatives and caregivers who have participated, and our many collaborators including those in the PVRI IDDI Patient Empowerment and Engagement Group

- David Badesch, University of Colorado
- Diana Haberle, Janssen
- Gabi Lowe, Jenna Lowe Trust/Patient Advocate
- Gerry Fischer, PHA Europe
- Hall Skaara, PHA Europe
- Helen Whitford, Alfred University Hospital, Melbourne
- HuangHuan, Aixike/Patient Rep, China
- Iain Armstrong, PHA UK
- Jamie Myrah, PHA Canada
- Jamie Strachan, The Dinosaur Trust
- Jeremy Durand, PHA Canada
- Luccilla Piccari, Hospital del Mar, Barcelona
- Luke Howard, Imperial College London
- Maurice Beghetti, Children's University Hospital, Switzerland
- Pisana Ferrari, Alliance for PH
- Prashant Bobhate, Kokilaben Dhirubhai Ambani, Mumbai
- Shahin Moledina, GOSH, London
- Shaun Clayton, PHA UK
- Sylvia Nikko, Bayer
- Tess Jewson, Patient Representative
- Virginia Gressin, Janssen
- Wendy Gin-Sing, Nurse Consultant

To make a data request and for other information, please go to

<https://pvri.link/phgps>

